Ozer Muhammet, Goksu Suleyman Yasin, Akagunduz Baran, George Andrew, Sahin Ilyas
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Division of Hematology and Oncology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cancers (Basel). 2023 Mar 16;15(6):1808. doi: 10.3390/cancers15061808.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Immune checkpoint inhibitors (ICIs) have become the new reference standard in first-line HCC treatment, replacing tyrosine kinase inhibitors (TKIs) such as sorafenib. Many clinical trials with different combinations are already in development to validate novel immunotherapies for the treatment of patients with HCC. Adoptive cell therapy (ACT), also known as cellular immunotherapy, with chimeric antigen receptors (CAR) or gene-modified T cells expressing novel T cell receptors (TCR) may represent a promising alternative approach to modify the immune system to recognize tumor cells with better clinical outcomes. In this review, we briefly discuss the overview of ACT as a promising treatment modality in HCC, along with recent updates of ongoing clinical trials.
肝细胞癌（HCC）是原发性肝癌最常见的类型。免疫检查点抑制剂（ICIs）已成为一线HCC治疗的新参考标准，取代了索拉非尼等酪氨酸激酶抑制剂（TKIs）。许多不同组合的临床试验正在开展，以验证用于治疗HCC患者的新型免疫疗法。过继性细胞疗法（ACT），也称为细胞免疫疗法，使用嵌合抗原受体（CAR）或表达新型T细胞受体（TCR）的基因修饰T细胞，可能是一种有前景的替代方法，可用于调节免疫系统以识别肿瘤细胞，并获得更好的临床结果。在本综述中，我们简要讨论了ACT作为一种有前景的HCC治疗方式的概况，以及正在进行的临床试验的最新进展。
